title: CD4(+) T Cell Response to Lamivudine, Stavudine and Nevirapine in Human Immunodeficiency Virus Infected Antiretroviral-Naive Men in Nigeria.
abstract: Increase of (≥) 50 CD4(+) T cells/μl in post-commencement of highly active antiretroviral therapy (HAART) is acceptable as indicator of therapeutic success (TS). We therefore hypothesized that median change in CD4 count of the TS and therapeutic failure (TF) groups were comparable after 3 months; and that no associations existed between HAART outcome and adherence to therapy. One hundred Human immunodeficiency virus (HIV) infected antiretroviral (ARV) naive men on lamivudine + stavudine + nevirapine at Federal Medical Centre (FMC), Lokoja, Kogi State, Nigeria were studied. Data of the men were obtained with interviewer-administered questionnaire forms. Their ethylene diamine tetra acetic acid (EDTA)-treated whole blood samples were analysed with Partec CyFlow(®) Counter for pre-HAART and follow-up CD4 counts. Adherence to the ARV regimen was recorded for each patient as self-reported. We used Mann-Whitney U test, Kruskal-Wallis, Wilcoxon's matched pair and CHI(2) statistical tests for analyses. Overall adherence rate was 95.0%. Though the median follow-up CD4 count was higher (P = 0.001) than the pre-HAART value; only 85% of the men attained TS (increase of ≥50 cells/μl) at follow-up. Median change in CD4 count (+104.0 cells/μl; n = 85) of the TS was higher (P = 0.001) than that (-8.0 cells/μl; n = 15) of TF group; the two groups were however, comparable in age (P = 0.17) and body weight (P = 0.96). Only adherence and pre-HAART CD4 counts were associated (P = 0.001) with HAART outcome; while only age apparently influenced (P = 0.01) adherence rate. Eighty-five percent of the men benefited from the HAART. The success was apparently due to adherence and less than or (≤) 200 pre-HAART CD4 counts; while age ≥40 years appearently reduced adherence level.
authors: Department of Biological Sciences, College of Science, Engineering and Technology, Osun State University, Osogbo, PMB 4494 Osun State Nigeria.
authors: Waidi Folorunso
authors: WF
authors: Sule
authors: Enejoh Simon
authors: ES
authors: Sani
keywords: Adherence; Antiretroviral therapy; CD4 count; Men; Nigeria
references: JAMA. 2001 Nov 28;286(20):2568-77
references: 11722271
references: J Acquir Immune Defic Syndr. 2004 Mar 1;35(3):261-8
references: 15076240
references: N Engl J Med. 1999 Dec 16;341(25):1865-73
references: 10601505
references: Arch Intern Med. 2003 Oct 13;163(18):2187-95
references: 14557216
references: HIV Med. 2006 Mar;7(2):99-104
references: 16420254
references: J Acquir Immune Defic Syndr. 2002 Sep 1;31 Suppl 1:S3-9; discussion S24-5
references: 12218438
references: JAMA. 2004 Jul 14;292(2):191-201
references: 15249568
references: Immunol Lett. 1999 Mar;66(1-3):207-11
references: 10203056
references: JAMA. 2006 Aug 16;296(7):769-81
references: 16905783
references: AIDS Res Hum Retroviruses. 2008 Mar;24(3):499-504
references: 18373435
references: JAMA. 2004 Jul 14;292(2):251-65
references: 15249575
references: Clin Diagn Lab Immunol. 2005 Apr;12(4):525-30
references: 15817761
references: Indian J Med Microbiol. 2008 Jul-Sep;26(3):256-8
references: 18695327
references: J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):553-8
references: 18285713
references: Immunol Today. 1993 Jul;14(7):340-4
references: 8363722
references: AIDS. 1999 Sep 10;13(13):1763-9
references: 10509579
references: Lancet. 2002 Jun 15;359(9323):2059-64
references: 12086758
references: JAMA. 2001 Nov 28;286(20):2560-7
references: 11722270
references: Nat Med. 1998 Feb;4(2):208-14
references: 9461195
references: Ann Intern Med. 2000 Jul 4;133(1):21-30
references: 10877736
references: Mem Inst Oswaldo Cruz. 1996 May-Jun;91(3):359-62
references: 9040856
references: Lancet. 2004 Apr 17;363(9417):1253-63
references: 15094269
references: J Acquir Immune Defic Syndr. 2001 Aug 1;27(4):372-6
references: 11468425